Compare DLTH & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | CNTB |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 128.6M |
| IPO Year | 2015 | 2020 |
| Metric | DLTH | CNTB |
|---|---|---|
| Price | $2.13 | $2.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 38.8K | ★ 89.3K |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $626,629,000.00 | $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,617.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $0.51 |
| 52 Week High | $4.66 | $3.28 |
| Indicator | DLTH | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 47.65 |
| Support Level | $2.10 | $2.09 |
| Resistance Level | $2.36 | $2.51 |
| Average True Range (ATR) | 0.15 | 0.23 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 38.79 | 15.00 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.